Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 195

1.

Why Is It so Hard to Do Good Science?

Dingledine R.

eNeuro. 2018 Sep 6;5(5). pii: ENEURO.0188-18.2018. doi: 10.1523/ENEURO.0188-18.2018. eCollection 2018 Sep-Oct.

2.

Beneficial Outcome of Urethane Treatment Following Status Epilepticus in a Rat Organophosphorus Toxicity Model.

Rojas A, Wang W, Glover A, Manji Z, Fu Y, Dingledine R.

eNeuro. 2018 Apr 17;5(2). pii: ENEURO.0070-18.2018. doi: 10.1523/ENEURO.0070-18.2018. eCollection 2018 Mar-Apr.

3.

Discovery of 2-Piperidinyl Phenyl Benzamides and Trisubstituted Pyrimidines as Positive Allosteric Modulators of the Prostaglandin Receptor EP2.

Jiang J, Van TM, Ganesh T, Dingledine R.

ACS Chem Neurosci. 2018 Apr 18;9(4):699-707. doi: 10.1021/acschemneuro.7b00486. Epub 2018 Jan 4.

PMID:
29292987
4.

Commonalities in epileptogenic processes from different acute brain insults: Do they translate?

Klein P, Dingledine R, Aronica E, Bernard C, Blümcke I, Boison D, Brodie MJ, Brooks-Kayal AR, Engel J Jr, Forcelli PA, Hirsch LJ, Kaminski RM, Klitgaard H, Kobow K, Lowenstein DH, Pearl PL, Pitkänen A, Puhakka N, Rogawski MA, Schmidt D, Sillanpää M, Sloviter RS, Steinhäuser C, Vezzani A, Walker MC, Löscher W.

Epilepsia. 2018 Jan;59(1):37-66. doi: 10.1111/epi.13965. Epub 2017 Dec 15. Review.

PMID:
29247482
5.

Neuroinflammatory targets and treatments for epilepsy validated in experimental models.

Aronica E, Bauer S, Bozzi Y, Caleo M, Dingledine R, Gorter JA, Henshall DC, Kaufer D, Koh S, Löscher W, Louboutin JP, Mishto M, Norwood BA, Palma E, Poulter MO, Terrone G, Vezzani A, Kaminski RM.

Epilepsia. 2017 Jul;58 Suppl 3:27-38. doi: 10.1111/epi.13783. Review.

6.

Transcriptional profile of hippocampal dentate granule cells in four rat epilepsy models.

Dingledine R, Coulter DA, Fritsch B, Gorter JA, Lelutiu N, McNamara J, Nadler JV, Pitkänen A, Rogawski MA, Skene P, Sloviter RS, Wang Y, Wadman WJ, Wasterlain C, Roopra A.

Sci Data. 2017 May 9;4:170061. doi: 10.1038/sdata.2017.61.

7.

Ethylatropine Bromide as a Peripherally Restricted Muscarinic Antagonist.

Rojas A, Ganesh T, Walker A, Dingledine R.

ACS Chem Neurosci. 2017 Apr 19;8(4):712-717. doi: 10.1021/acschemneuro.6b00334. Epub 2017 Jan 6.

8.

Infiltrating monocytes promote brain inflammation and exacerbate neuronal damage after status epilepticus.

Varvel NH, Neher JJ, Bosch A, Wang W, Ransohoff RM, Miller RJ, Dingledine R.

Proc Natl Acad Sci U S A. 2016 Sep 20;113(38):E5665-74. doi: 10.1073/pnas.1604263113. Epub 2016 Sep 6.

9.

Inhibition of the prostaglandin E2 receptor EP2 prevents status epilepticus-induced deficits in the novel object recognition task in rats.

Rojas A, Ganesh T, Manji Z, O'neill T, Dingledine R.

Neuropharmacology. 2016 Nov;110(Pt A):419-430. doi: 10.1016/j.neuropharm.2016.07.028. Epub 2016 Jul 29.

10.

A New Approach for Epilepsy.

Dingledine R, Hassel B.

Cerebrum. 2016 May 1;2016. pii: cer-07-16. eCollection 2016 May-Jun.

11.

2014 Epilepsy Benchmarks Area IV: Limit or Prevent Adverse Consequence of Seizures and Their Treatment Across The Lifespan.

Goldman AM, LaFrance WC Jr, Benke T, Asato M, Drane D, Pack A, Syed T, Doss R, Lhatoo S, Fureman B, Dingledine R; American Epilepsy Society (AES)/National Institute of Neurological Disorders and Stroke (NINDS) Epilepsy Benchmark Stewards.

Epilepsy Curr. 2016 May-Jun;16(3):198-205. doi: 10.5698/1535-7511-16.3.198. No abstract available.

12.

2014 Epilepsy Benchmarks Area III: Improve Treatment Options for Controlling Seizures and Epilepsy-Related Conditions Without Side Effects.

Dlugos D, Worrell G, Davis K, Stacey W, Szaflarski J, Kanner A, Sunderam S, Rogawski M, Jackson-Ayotunde P, Loddenkemper T, Diehl B, Fureman B, Dingledine R; Epilepsy Benchmark Stewards.

Epilepsy Curr. 2016 May-Jun;16(3):192-7. doi: 10.5698/1535-7511-16.3.192. No abstract available.

13.

2014 Epilepsy Benchmarks Area II: Prevent Epilepsy and Its Progression.

Galanopoulou AS, Wong M, Binder D, Hartman AL, Powell EM, Roopra A, Staba R, Vezzani A, Fureman B, Dingledine R; American Epilepsy Society (AES)/National Institute of Neurological Disorders and Stroke (NINDS) Epilepsy Benchmarks Stewards.

Epilepsy Curr. 2016 May-Jun;16(3):187-91. doi: 10.5698/1535-7511-16.3.187. No abstract available.

14.

2014 Epilepsy Benchmarks Area I: Understanding the Causes of the Epilepsies and Epilepsy-Related Neurologic, Psychiatric, and Somatic Conditions.

Caplan R, Mefford H, Berl M, Chang B, Lin J, Mazarati A, Fureman B, Dingledine R; American Epilepsy Society (AES)/National Institute of Neurological Disorders and Stroke (NINDS) Epilepsy Benchmark Stewards.

Epilepsy Curr. 2016 May-Jun;16(3):182-6. doi: 10.5698/1535-7511-16.3.182. No abstract available.

15.

2014 Epilepsy Benchmarks: Progress and Opportunities.

Long C, Fureman B, Dingledine R.

Epilepsy Curr. 2016 May-Jun;16(3):179-81. doi: 10.5698/1535-7511-16.3.179. No abstract available.

16.

Immunity and inflammation in status epilepticus and its sequelae: possibilities for therapeutic application.

Vezzani A, Dingledine R, Rossetti AO.

Expert Rev Neurother. 2015;15(9):1081-92. doi: 10.1586/14737175.2015.1079130. Review.

17.

The First 50 Years of Molecular Pharmacology.

Brown JH, Catterall WA, Conn PJ, Cull-Candy SG, Dingledine R, Harden TK, Insel PA, Milligan G, Traynelis SF.

Mol Pharmacol. 2015 Jul;88(1):139-40. doi: 10.1124/mol.115.099564. Epub 2015 May 5. Review.

18.

EP2 Receptor Signaling Regulates Microglia Death.

Fu Y, Yang MS, Jiang J, Ganesh T, Joe E, Dingledine R.

Mol Pharmacol. 2015 Jul;88(1):161-70. doi: 10.1124/mol.115.098202. Epub 2015 Feb 25.

19.

Uptake and metabolism of fructose by rat neocortical cells in vivo and by isolated nerve terminals in vitro.

Hassel B, Elsais A, Frøland AS, Taubøll E, Gjerstad L, Quan Y, Dingledine R, Rise F.

J Neurochem. 2015 May;133(4):572-81. doi: 10.1111/jnc.13079. Epub 2015 Mar 13.

20.

Inhibition of the prostaglandin EP2 receptor is neuroprotective and accelerates functional recovery in a rat model of organophosphorus induced status epilepticus.

Rojas A, Ganesh T, Lelutiu N, Gueorguieva P, Dingledine R.

Neuropharmacology. 2015 Jun;93:15-27. doi: 10.1016/j.neuropharm.2015.01.017. Epub 2015 Feb 3.

21.

Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus.

Jiang J, Yang MS, Quan Y, Gueorguieva P, Ganesh T, Dingledine R.

Neurobiol Dis. 2015 Apr;76:126-136. doi: 10.1016/j.nbd.2014.12.032. Epub 2015 Jan 17.

22.

Candidate drug targets for prevention or modification of epilepsy.

Varvel NH, Jiang J, Dingledine R.

Annu Rev Pharmacol Toxicol. 2015;55:229-47. doi: 10.1146/annurev-pharmtox-010814-124607. Epub 2014 Aug 25. Review.

23.

When and how do seizures kill neurons, and is cell death relevant to epileptogenesis?

Dingledine R, Varvel NH, Dudek FE.

Adv Exp Med Biol. 2014;813:109-22. doi: 10.1007/978-94-017-8914-1_9. Review.

24.

The prostaglandin EP1 receptor potentiates kainate receptor activation via a protein kinase C pathway and exacerbates status epilepticus.

Rojas A, Gueorguieva P, Lelutiu N, Quan Y, Shaw R, Dingledine R.

Neurobiol Dis. 2014 Oct;70:74-89. doi: 10.1016/j.nbd.2014.06.004. Epub 2014 Jun 19.

25.

Development of second generation EP2 antagonists with high selectivity.

Ganesh T, Jiang J, Dingledine R.

Eur J Med Chem. 2014 Jul 23;82:521-35. doi: 10.1016/j.ejmech.2014.05.076. Epub 2014 Jun 3.

26.

Lead optimization studies of cinnamic amide EP2 antagonists.

Ganesh T, Jiang J, Yang MS, Dingledine R.

J Med Chem. 2014 May 22;57(10):4173-84. doi: 10.1021/jm5000672. Epub 2014 May 5.

27.

Cyclooxygenase-2 in epilepsy.

Rojas A, Jiang J, Ganesh T, Yang MS, Lelutiu N, Gueorguieva P, Dingledine R.

Epilepsia. 2014 Jan;55(1):17-25. doi: 10.1111/epi.12461. Epub 2013 Nov 8. Review.

28.

Discovery and characterization of carbamothioylacrylamides as EP2 selective antagonists.

Ganesh T, Jiang J, Shashidharamurthy R, Dingledine R.

ACS Med Chem Lett. 2013 Jul 11;4(7):616-621.

29.

Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection.

Jiang J, Dingledine R.

Trends Pharmacol Sci. 2013 Jul;34(7):413-23. doi: 10.1016/j.tips.2013.05.003. Epub 2013 Jun 21. Review.

30.

EP2 receptor signaling pathways regulate classical activation of microglia.

Quan Y, Jiang J, Dingledine R.

J Biol Chem. 2013 Mar 29;288(13):9293-302. doi: 10.1074/jbc.M113.455816. Epub 2013 Feb 12.

31.

Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation.

Jiang J, Quan Y, Ganesh T, Pouliot WA, Dudek FE, Dingledine R.

Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3591-6. doi: 10.1073/pnas.1218498110. Epub 2013 Feb 11.

32.

Ionotropic glutamate receptors: regulation by G-protein-coupled receptors.

Rojas A, Dingledine R.

Mol Pharmacol. 2013 Apr;83(4):746-52. doi: 10.1124/mol.112.083352. Epub 2013 Jan 24. Review.

33.

Avram Goldstein: the founder of molecular pharmacology.

Cox B, Han JS, Dingledine R.

Mol Pharmacol. 2013 Apr;83(4):720-2. doi: 10.1124/mol.112.084640. Epub 2013 Jan 17. No abstract available.

34.

Epigenetics and epilepsy.

Roopra A, Dingledine R, Hsieh J.

Epilepsia. 2012 Dec;53 Suppl 9:2-10. doi: 10.1111/epi.12030. Review.

35.

Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation.

Jiang J, Dingledine R.

J Pharmacol Exp Ther. 2013 Feb;344(2):360-7. doi: 10.1124/jpet.112.200444. Epub 2012 Nov 28.

36.

Activation of group I metabotropic glutamate receptors potentiates heteromeric kainate receptors.

Rojas A, Wetherington J, Shaw R, Serrano G, Swanger S, Dingledine R.

Mol Pharmacol. 2013 Jan;83(1):106-21. doi: 10.1124/mol.112.081802. Epub 2012 Oct 11.

37.

Glutamatergic Mechanisms Related to Epilepsy: Ionotropic Receptors.

Dingledine R.

In: Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV, editors. Jasper's Basic Mechanisms of the Epilepsies [Internet]. 4th edition. Bethesda (MD): National Center for Biotechnology Information (US); 2012.

38.

Reduction in delayed mortality and subtle improvement in retrograde memory performance in pilocarpine-treated mice with conditional neuronal deletion of cyclooxygenase-2 gene.

Levin JR, Serrano G, Dingledine R.

Epilepsia. 2012 Aug;53(8):1411-20. doi: 10.1111/j.1528-1167.2012.03584.x. Epub 2012 Jul 10.

39.

The role of inflammation in epileptogenesis.

Vezzani A, Friedman A, Dingledine RJ.

Neuropharmacology. 2013 Jun;69:16-24. doi: 10.1016/j.neuropharm.2012.04.004. Epub 2012 Apr 13. Review.

40.

Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2.

Jiang J, Ganesh T, Du Y, Quan Y, Serrano G, Qui M, Speigel I, Rojas A, Lelutiu N, Dingledine R.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3149-54. doi: 10.1073/pnas.1120195109. Epub 2012 Feb 8.

41.

Ablation of cyclooxygenase-2 in forebrain neurons is neuroprotective and dampens brain inflammation after status epilepticus.

Serrano GE, Lelutiu N, Rojas A, Cochi S, Shaw R, Makinson CD, Wang D, FitzGerald GA, Dingledine R.

J Neurosci. 2011 Oct 19;31(42):14850-60. doi: 10.1523/JNEUROSCI.3922-11.2011.

42.

Direct detection of a single evoked action potential with MRS in Lumbricus terrestris.

Poplawsky AJ, Dingledine R, Hu XP.

NMR Biomed. 2012 Jan;25(1):123-30. doi: 10.1002/nbm.1724. Epub 2011 Jul 5.

43.

Molecular cascades that mediate the influence of inflammation on epilepsy.

Friedman A, Dingledine R.

Epilepsia. 2011 May;52 Suppl 3:33-9. doi: 10.1111/j.1528-1167.2011.03034.x. Review.

44.

Blocking eIF4E-eIF4G interaction as a strategy to impair coronavirus replication.

Cencic R, Desforges M, Hall DR, Kozakov D, Du Y, Min J, Dingledine R, Fu H, Vajda S, Talbot PJ, Pelletier J.

J Virol. 2011 Jul;85(13):6381-9. doi: 10.1128/JVI.00078-11. Epub 2011 Apr 20.

45.

A dual-readout F2 assay that combines fluorescence resonance energy transfer and fluorescence polarization for monitoring bimolecular interactions.

Du Y, Nikolovska-Coleska Z, Qui M, Li L, Lewis I, Dingledine R, Stuckey JA, Krajewski K, Roller PP, Wang S, Fu H.

Assay Drug Dev Technol. 2011 Aug;9(4):382-93. doi: 10.1089/adt.2010.0292. Epub 2011 Mar 11.

46.

Unraveling the role of zinc in memory.

Mott DD, Dingledine R.

Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3103-4. doi: 10.1073/pnas.1100323108. Epub 2011 Feb 14. No abstract available.

47.

Induction and expression rules of synaptic plasticity in hippocampal interneurons.

Laezza F, Dingledine R.

Neuropharmacology. 2011 Apr;60(5):720-9. doi: 10.1016/j.neuropharm.2010.12.016. Epub 2010 Dec 30. Review.

48.

Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F.

Cencic R, Hall DR, Robert F, Du Y, Min J, Li L, Qui M, Lewis I, Kurtkaya S, Dingledine R, Fu H, Kozakov D, Vajda S, Pelletier J.

Proc Natl Acad Sci U S A. 2011 Jan 18;108(3):1046-51. doi: 10.1073/pnas.1011477108. Epub 2010 Dec 29. Erratum in: Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6689.

49.

Distinct 3'UTRs differentially regulate activity-dependent translation of brain-derived neurotrophic factor (BDNF).

Lau AG, Irier HA, Gu J, Tian D, Ku L, Liu G, Xia M, Fritsch B, Zheng JQ, Dingledine R, Xu B, Lu B, Feng Y.

Proc Natl Acad Sci U S A. 2010 Sep 7;107(36):15945-50. doi: 10.1073/pnas.1002929107. Epub 2010 Aug 23.

50.

Glutamate receptor ion channels: structure, regulation, and function.

Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, Hansen KB, Yuan H, Myers SJ, Dingledine R.

Pharmacol Rev. 2010 Sep;62(3):405-96. doi: 10.1124/pr.109.002451. Review. Erratum in: Pharmacol Rev. 2014 Oct;66(4):1141.

Supplemental Content

Loading ...
Support Center